📊 INMB Key Takeaways
Is Inmune Bio, Inc. (INMB) a Good Investment?
Inmune Bio is a pre-revenue/early-stage biotech company with severely negative profitability and cash burn, burning approximately $20.5M in free cash flow annually against minimal revenue of $50K. Despite adequate short-term liquidity (4.17x current ratio and $27.7M cash), the company faces existential runway concerns at current burn rates, with only 16-18 months of cash remaining if burn continues unabated.
Inmune Bio’s fundamentals are weak: revenue is negligible and down sharply, operating and net losses are very large relative to its asset base, and free cash flow remains deeply negative. The main offset is a relatively strong near-term liquidity position, with cash making up most of assets and current ratios above 4x, but absent a meaningful improvement in clinical/commercial execution, the business currently relies on cash consumption rather than durable operating performance.
Why Buy Inmune Bio, Inc. Stock? INMB Key Strengths
- Strong current ratio of 4.17x indicates short-term liquidity to fund operations
- Positive stockholders equity of $25.4M provides modest balance sheet cushion
- Cash position of $27.7M adequate for near-term R&D and clinical trial funding
- Strong short-term liquidity, with $27.73M of cash and 4.17x current and quick ratios
- Liabilities are modest relative to total assets, leaving positive equity of $25.38M
- Debt/equity of 0.59x is manageable for now compared with its existing cash balance
INMB Stock Risks: Inmune Bio, Inc. Investment Risks
- Massive operating losses of -$41.9M with operating margin of -83,818% indicating unsustainable business model
- Severe cash burn of -$20.5M annually with only ~16 months of runway at current burn rates
- Revenue collapse of -91% YoY coupled with zero revenue growth trajectory and no clear path to profitability
- Long-term debt of $15M represents 59% of equity and compounds financing burden
- No insider buying activity in 90 days suggests lack of management confidence
- Negative interest coverage of -69.0x means operating cash flow cannot service debt obligations
- Revenue collapsed 91.0% year over year to just $50K, indicating very weak operating scale and poor growth quality
- Losses are severe, with operating income of -$41.91M, net income of -$40.67M, and extremely negative margins
- Cash burn is substantial, with operating cash flow of -$19.64M and free cash flow of -$20.54M, raising future funding risk
Key Metrics to Watch
- Monthly cash burn rate and runway extension announcements
- Clinical trial progress and pipeline advancement milestones
- Revenue trajectory and any commercial partnerships or licensing deals
- Cash position depletion timeline and potential financing needs
- Operating expense reduction and burn optimization initiatives
- Quarterly operating cash burn relative to cash balance
- Revenue traction and whether operating losses begin narrowing materially
Inmune Bio, Inc. (INMB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.17x current ratio provides a solid financial cushion.
INMB Profit Margin, ROE & Profitability Analysis
INMB vs Healthcare Sector: How Inmune Bio, Inc. Compares
How Inmune Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inmune Bio, Inc. Stock Overvalued? INMB Valuation Analysis 2026
Based on fundamental analysis, Inmune Bio, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inmune Bio, Inc. Balance Sheet: INMB Debt, Cash & Liquidity
INMB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inmune Bio, Inc.'s revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-2.11 indicates the company is currently unprofitable.
INMB Revenue Growth, EPS Growth & YoY Performance
INMB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.0K | -$6.5M | $-0.24 |
| Q2 2025 | $14.0K | -$9.7M | $-0.50 |
| Q1 2025 | $14.0K | -$9.7M | $-0.43 |
| Q3 2024 | $14.0K | -$6.5M | $-0.48 |
| Q2 2024 | $14.0K | -$6.5M | $-0.36 |
| Q1 2024 | $14.0K | -$6.5M | $-0.36 |
| Q3 2023 | $43.0K | -$6.5M | $-0.43 |
| Q2 2023 | $16.0K | -$6.5M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inmune Bio, Inc. Dividends, Buybacks & Capital Allocation
INMB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inmune Bio, Inc. (CIK: 0001711754)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INMB
What is the AI rating for INMB?
Inmune Bio, Inc. (INMB) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INMB's key strengths?
Claude: Strong current ratio of 4.17x indicates short-term liquidity to fund operations. Positive stockholders equity of $25.4M provides modest balance sheet cushion. ChatGPT: Strong short-term liquidity, with $27.73M of cash and 4.17x current and quick ratios. Liabilities are modest relative to total assets, leaving positive equity of $25.38M.
What are the risks of investing in INMB?
Claude: Massive operating losses of -$41.9M with operating margin of -83,818% indicating unsustainable business model. Severe cash burn of -$20.5M annually with only ~16 months of runway at current burn rates. ChatGPT: Revenue collapsed 91.0% year over year to just $50K, indicating very weak operating scale and poor growth quality. Losses are severe, with operating income of -$41.91M, net income of -$40.67M, and extremely negative margins.
What is INMB's revenue and growth?
Inmune Bio, Inc. reported revenue of $50.0K.
Does INMB pay dividends?
Inmune Bio, Inc. does not currently pay dividends.
Where can I find INMB SEC filings?
Official SEC filings for Inmune Bio, Inc. (CIK: 0001711754) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INMB's EPS?
Inmune Bio, Inc. has a diluted EPS of $-1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INMB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inmune Bio, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INMB stock overvalued or undervalued?
Valuation metrics for INMB: ROE of -160.3% (sector avg: 15%), net margin of -81,338.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INMB stock in 2026?
Our dual AI analysis gives Inmune Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INMB's free cash flow?
Inmune Bio, Inc.'s operating cash flow is $-19.6M, with capital expenditures of $899.0K. FCF margin is -41,074.0%.
How does INMB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -81,338.0% (avg: 12%), ROE -160.3% (avg: 15%), current ratio 4.17 (avg: 2).